SUMMIT THERAPEU/S (NASDAQ:SMMT) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) from a buy rating to a hold rating in a report published on Wednesday morning, reports.

According to Zacks, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom. “

Several other research analysts have also weighed in on the company. Oppenheimer set a $10.00 price target on Motus GI and gave the stock a buy rating in a research report on Thursday, March 28th. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. HC Wainwright lifted their target price on Largo Resources from C$5.10 to C$5.20 in a research note on Thursday, March 28th. Finally, TheStreet upgraded SUMMIT THERAPEU/S from a d rating to a c- rating in a research note on Thursday, June 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. SUMMIT THERAPEU/S has an average rating of Hold and a consensus price target of $2.17.

NASDAQ:SMMT opened at $1.31 on Wednesday. The firm has a market cap of $18.14 million, a price-to-earnings ratio of 1.56 and a beta of 1.21. SUMMIT THERAPEU/S has a twelve month low of $1.10 and a twelve month high of $2.68. The business’s 50 day moving average is $1.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.93 and a quick ratio of 3.93.

SUMMIT THERAPEU/S (NASDAQ:SMMT) last posted its quarterly earnings results on Wednesday, June 12th. The company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.11. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $4.34 million. SUMMIT THERAPEU/S had a return on equity of 26.31% and a net margin of 24.32%. As a group, equities research analysts forecast that SUMMIT THERAPEU/S will post -1.08 EPS for the current year.


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Featured Article: Options Trading – What is a Straddle?

Get a free copy of the Zacks research report on SUMMIT THERAPEU/S (SMMT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with's FREE daily email newsletter.